Mechanisms and Factors Responsible for the Inhibition of Transposons During Fetal Gonad Development in Humans

Mechanisms and Factors Responsible for the Inhibition of Transposons During Fetal Gonad Development in Humans

This is a single-centre study over 36 months for the inclusion of 30 patients. The selection and inclusion of patients will take place according to the criterion of Medical Termination of Pregnancy at 4 different gestational ages (8-12 weeks of gestation (WG)), 13-16 WG, 17-23 WG and 25-35 WG. The tissue analysed will principally be the gonads, other somatic tissue will also be systematically harvested in parallel (liver and psoas muscle) for control purposes. The gonads will be subjected to molecular biology analyses destined to quantify the expression of transposons and their inhibitors.

Inclusion Criteria:

• Couple or mother who has provided written informed consent
• Foetus between 10 and 37 weeks of amenorrhea (WA)
• Male foetus
• Foetus obtained following medical termination of pregnancy or voluntary termination of pregnancy

Exclusion Criteria:

• persons without national health insurance cover
• foetus presenting aneuploidy
• foetus presenting a malformation of the genital organs